JPH10158186A - Antiinflammatory analgesic patch - Google Patents
Antiinflammatory analgesic patchInfo
- Publication number
- JPH10158186A JPH10158186A JP8319144A JP31914496A JPH10158186A JP H10158186 A JPH10158186 A JP H10158186A JP 8319144 A JP8319144 A JP 8319144A JP 31914496 A JP31914496 A JP 31914496A JP H10158186 A JPH10158186 A JP H10158186A
- Authority
- JP
- Japan
- Prior art keywords
- iris
- patch
- weight
- component
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960000905 indomethacin Drugs 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000243 solution Substances 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 241001113425 Iridaceae Species 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- -1 fatty acid esters Chemical class 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920001748 polybutylene Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000004101 Iris pallida Species 0.000 description 1
- 241001627144 Iris versicolor Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- KLMDYFUUSKOJAX-UHFFFAOYSA-K aluminum;acetate;dihydroxide Chemical compound CC(=O)O[Al](O)O KLMDYFUUSKOJAX-UHFFFAOYSA-K 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、打撲、捻挫、関節痛、
肩こり、腰痛などの消炎鎮痛に用いられる貼付剤に関す
るものである。The present invention relates to bruises, sprains, joint pain,
The present invention relates to a patch used for anti-inflammatory analgesia such as stiff shoulders and back pain.
【0002】[0002]
【従来の技術】インドメタシンは1-(p-クロロヘ゛ンソ゛イル)-5-メ
トキシ-2-メチルイント゛ール-3-酢酸の化学名を有する非ステロイド
系消炎鎮痛剤である。インドメタシンは優れた消炎鎮痛
効果を有するものの、経口投与では胃腸障害など副作用
が認められている。これら副作用の軽減を図るため、従
来より消炎鎮痛軟膏や水性パップ剤等の外用剤の検討が
なされている。一方、イリス根は芳香成分を含み、ヨー
ロッパ等で香水の原料として用いられていた。2. Description of the Prior Art Indomethacin is a non-steroidal anti-inflammatory analgesic having the chemical name of 1- (p-chlorobenzodiyl) -5-methoxy-2-methylindole-3-acetic acid. Although indomethacin has an excellent anti-inflammatory and analgesic effect, side effects such as gastrointestinal disorders have been observed when administered orally. In order to reduce these side effects, external preparations such as anti-inflammatory analgesic ointment and aqueous cataplasm have been studied. On the other hand, iris root contains an aromatic component and has been used as a raw material of perfume in Europe and the like.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、十分
な有効性を持つ消炎鎮痛外用剤を開発することにある。SUMMARY OF THE INVENTION An object of the present invention is to develop an anti-inflammatory analgesic external preparation having sufficient efficacy.
【0004】[0004]
【課題を解決するための手段】本発明者らは鋭意研究を
進めた結果、インドメタシンとイリス根抽出液及び/又
はそのエキスとを併用して経皮投与すれば、それぞれを
単独で用いるよりも優れた鎮痛作用を発揮することを見
出し、本発明を完成した。すなわち、本発明は、(a)
インドメタシン及び(b)イリス根抽出液及びそのエキ
スからなる群より選ばれる1種または2種を配合した消
炎鎮痛貼付剤である。Means for Solving the Problems As a result of intense research, the present inventors have found that if indomethacin and iris root extract and / or its extract are transdermally administered in combination, each of them is more effective than using each alone. The present inventors have found that they exhibit an excellent analgesic effect, and have completed the present invention. That is, the present invention provides (a)
An anti-inflammatory analgesic patch comprising one or two selected from the group consisting of indomethacin and (b) iris root extract and extract thereof.
【0005】本発明におけるイリス根は、アヤメ科(Iri
daceae)アヤメ属(Iris属)の植物であるムラサキイリス
(I.germancia Lam.)、ニオイイリス(I.florentia L.)、
及びシボリイリス(I.pallida L.)またはその他の同属植
物の根茎からの抽出物(水、水・アルコール等の混液、
アルコール)、またはその抽出物を用いて製したエキス
(乾燥エキスまたは軟エキス)を用いることができる。
インドメタシンは貼付剤中に0.01〜5.0重量%配合
する事が好適であり,好ましくは0.2〜2.0重量%で
ある。また、使用するイリス根抽出物またはエキスの配
合割合としては、原生薬換算でインドメタシン1重量部
に対して、0.001〜10重量部である。イリス根エ
キスの配合量が10重量部より多くなると製剤の着色や
皮膚刺激が発現するため好ましくない。また、0.00
1重量部未満では有効な作用が認められないため望まし
くない。[0005] In the present invention, the iris root is an iris (Iri
daceae) Purple iris, a plant of the genus Iris
(I.germancia Lam.), Smelt Iris (I.florentia L.),
And the extract from the rhizome of Ivory iris (I. pallida L.) or other congener plants (water, a mixture of water and alcohol,
(Alcohol) or an extract (dry extract or soft extract) produced using the extract thereof.
Indomethacin is preferably incorporated in the patch in an amount of 0.01 to 5.0% by weight, and more preferably 0.2 to 2.0% by weight. The mixing ratio of the iris root extract or extract used is 0.001 to 10 parts by weight based on 1 part by weight of indomethacin in terms of a crude drug. If the amount of the iris root extract is more than 10 parts by weight, coloring of the preparation and skin irritation occur, which is not preferable. Also, 0.00
If the amount is less than 1 part by weight, no effective action is observed, which is not desirable.
【0006】本発明の消炎鎮痛貼付剤においては、粘着
剤、充填剤、可塑剤、保湿剤、賦形剤、界面活性剤、防
腐剤、溶解補助剤、吸収促進剤、架橋剤、pH調整剤、
安定化剤等、通常外用剤として用いられる成分を本発明
の効果が損なわれない範囲で配合することができる。In the anti-inflammatory analgesic patch of the present invention, an adhesive, a filler, a plasticizer, a humectant, an excipient, a surfactant, a preservative, a solubilizer, an absorption enhancer, a crosslinking agent, a pH adjuster ,
Components normally used as external preparations, such as stabilizers, can be blended within a range that does not impair the effects of the present invention.
【0007】粘着剤としては、ポリアクリル酸、ポリア
クリル酸ナトリウム、ゼラチン、アラビアゴム、ポリビ
ニルアルコール、ポリビニルピロリドン、カルボキシメ
チルセルロースナトリウム、カルボキシビニルポリマ
ー、ヒドロキシメチルセルロース、アルギン酸ナトリウ
ム、キサンタンガム等の水溶性高分子化合物、天然ゴ
ム、水添ロジン、SBR(スチレンブタジエンゴム)、
SIS(スチレンイソプレンブロック共重合体ゴム)ポ
リイソブチレンゴム、ポリイソプレンゴム等の合成ゴ
ム、アクリル酸エステル、メタアクリル酸エステル等ア
クリル系粘着剤、シリコーンゴム及びレジン等のシリコ
ーン粘着剤等が使用できる。Examples of the adhesive include water-soluble polymer compounds such as polyacrylic acid, sodium polyacrylate, gelatin, gum arabic, polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, carboxyvinyl polymer, hydroxymethyl cellulose, sodium alginate, xanthan gum and the like. , Natural rubber, hydrogenated rosin, SBR (styrene butadiene rubber),
SIS (styrene isoprene block copolymer rubber) Synthetic rubbers such as polyisobutylene rubber and polyisoprene rubber, acrylic pressure-sensitive adhesives such as acrylic acid ester and methacrylic acid ester, and silicone pressure-sensitive adhesives such as silicone rubber and resin can be used.
【0008】また、充填剤としては無水ケイ酸、酸化チ
タン、ケイ酸アルミニウム、酸化亜鉛、カオリンなどが
挙げられる。可塑剤としては、ミリスチン酸、ラウリン
酸、オレイン酸等の脂肪酸、ミリスチン酸イソプロピ
ル、アジピン酸ジイソプロピル、セバシン酸ジエチル等
の脂肪酸エステル、ラノリン、流動パラフィン、ポリブ
チレン等が使用される。架橋剤としては、水酸化アルミ
ニウム、アルミニウムグリシネート、ジヒドロキシアル
ミニウムアセテート、ケイ酸アルミン酸マグネシウム等
が使用される。[0008] Examples of the filler include silicic anhydride, titanium oxide, aluminum silicate, zinc oxide and kaolin. As the plasticizer, fatty acids such as myristic acid, lauric acid and oleic acid, fatty acid esters such as isopropyl myristate, diisopropyl adipate and diethyl sebacate, lanolin, liquid paraffin, polybutylene and the like are used. As a cross-linking agent, aluminum hydroxide, aluminum glycinate, dihydroxyaluminum acetate, magnesium aluminate silicate, or the like is used.
【0009】保湿剤としては、グリセリン、プロピレン
グリコール、ブチレングリコール、マクロゴール、ソル
ビトール、乳酸ナトリウム等が使用される。賦形剤とし
ては、カオリン、ベントナイト、酸化亜鉛、酸化チタ
ン、無水ケイ酸等が使用される。界面活性剤としては、
ポリオキシエチレンソルビタン脂肪酸エステル(例えば
ポリソルベート80、ポリソルベート60など)、ポリ
オキシエチレン硬化ヒマシ油、ポリオキシエチレングリ
セリン脂肪酸エステル、ポリオキシエチレングリコール
脂肪酸エステル、ポリオキシエチレンポリオキシプロピ
アルキルエーテル、ポリオキシエチレングリコールエー
テル、ソルビタン脂肪酸エステル、グリセリン脂肪酸エ
ステル等が挙げられる。As humectants, glycerin, propylene glycol, butylene glycol, macrogol, sorbitol, sodium lactate and the like are used. As the excipient, kaolin, bentonite, zinc oxide, titanium oxide, silicic anhydride and the like are used. As a surfactant,
Polyoxyethylene sorbitan fatty acid ester (for example, polysorbate 80, polysorbate 60, etc.), polyoxyethylene hydrogenated castor oil, polyoxyethylene glycerin fatty acid ester, polyoxyethylene glycol fatty acid ester, polyoxyethylene polyoxypropyl alkyl ether, polyoxyethylene glycol Ether, sorbitan fatty acid ester, glycerin fatty acid ester and the like can be mentioned.
【0010】防腐剤としてはパラオキシ安息香酸エステ
ル類(例えばパラオキシ安息香酸メチルなど)などが挙
げられる。pH調整剤としてはクエン酸、リンゴ酸、酒
石酸、乳酸等が挙げられる。安定化剤としては、ジブチ
ルヒドロキシトルエン(BHT)、ブチルヒドロキシア
ニソール、エチレンジアミン四酢酸二ナトリウム(ED
TA−2Na)、亜硫酸ナトリウム等が配合できる。Examples of the preservative include paraoxybenzoic acid esters (for example, methyl paraoxybenzoate). Examples of the pH adjuster include citric acid, malic acid, tartaric acid, lactic acid and the like. As stabilizers, dibutylhydroxytoluene (BHT), butylhydroxyanisole, disodium ethylenediaminetetraacetate (ED
TA-2Na), sodium sulfite, and the like.
【0011】更に上記成分に加えて、サリチル酸メチ
ル、サリチル酸グリコール等のサリチル酸エステル類、
トウガラシ末、トウガラシエキス、ノニル酸ワニリルア
ミド、各種佐薬としてカンフル、メントール、ハッカ
油、酢酸トコフェロール、アズレン、グリチルレチン酸
等が配合できる。Further, in addition to the above components, salicylic esters such as methyl salicylate and glycol salicylate;
Capsicum powder, capsicum extract, vanillyl amide nonylate, camphor, menthol, peppermint oil, tocopherol acetate, azulene, glycyrrhetinic acid and the like as various adjuvants can be blended.
【0012】[0012]
【発明の効果】本発明により得られた消炎鎮痛貼付剤に
より、対象疾患である打撲、捻挫、筋肉痛、肩こり及び
腰痛に対して優れた鎮痛作用を有する貼付剤を提供でき
るようになった。According to the anti-inflammatory analgesic patch obtained by the present invention, a patch having an excellent analgesic effect on the target diseases such as bruise, sprain, muscle pain, stiff shoulder and low back pain can be provided.
【0013】[0013]
【実施例】以下、実施例、比較例及び試験例を挙げて、
本発明を更に詳細に説明する。 (実施例1)ポリアクリル酸6.0重量部及びポリアク
リル酸ナトリウム5.0重量部に無水ケイ酸0.5重量部
を加えた後、プロピレングリコール7.0重量部を加え
て均一に分散し、EDTA−2Na0.03重量部を予
め溶解した精製水65重量部に加えて均一に溶解した。
これにポリオキシエチレンソルビタンモノステアレート
0.3重量部を加熱溶解した後、イリス根エキス2.0重
量部、インドメタシン1.0重量部、アルミニウムグリ
シネート0.3重量部を均一に分散した液を加えて均一
に混合し、貼付剤膏体とした。この膏体を不織布に均一
の厚さに塗布した後、ライナーを貼り合わせて裁断し、
貼付剤とした。The following examples, comparative examples and test examples are given.
The present invention will be described in more detail. Example 1 After adding 0.5 parts by weight of silicic anhydride to 6.0 parts by weight of polyacrylic acid and 5.0 parts by weight of sodium polyacrylate, 7.0 parts by weight of propylene glycol was added and dispersed uniformly. Then, 0.03 parts by weight of EDTA-2Na was added to 65 parts by weight of purified water previously dissolved, and uniformly dissolved.
After heating and dissolving 0.3 parts by weight of polyoxyethylene sorbitan monostearate, 2.0 parts by weight of iris root extract, 1.0 parts by weight of indomethacin, and 0.3 parts by weight of aluminum glycinate are uniformly dispersed. Was added and mixed uniformly to obtain a patch. After applying this plaster to the nonwoven fabric to a uniform thickness, the liner is attached and cut,
It was a patch.
【0014】(実施例2)天然ゴム30.0重量部、ポ
リイソブチレン30.0重量部、ポリブチレン10.0重
量部、酸化チタン6.0重量部、水添ロジン35.0重量
部、ラノリン4.0重量部を均一に混合した。別に、B
HT3.0重量部を加熱溶解した後、イリス根エキス8.
5重量部、インドメタシン8.5重量部を均一に分散し
た液を加えて、混合し貼付剤膏体とした。この膏体を布
に均一の厚さに塗布した後、ライナーを貼り合わせて裁
断し、硬膏剤とした。Example 2 30.0 parts by weight of natural rubber, 30.0 parts by weight of polyisobutylene, 10.0 parts by weight of polybutylene, 6.0 parts by weight of titanium oxide, 35.0 parts by weight of hydrogenated rosin, lanolin 4 0.0 parts by weight were uniformly mixed. Separately, B
After heat dissolving 3.0 parts by weight of HT, Iris root extract 8.
A solution in which 5 parts by weight and indomethacin 8.5 parts by weight were uniformly dispersed was added and mixed to obtain a plaster. After this plaster was applied to a cloth to a uniform thickness, a liner was attached and cut to obtain a plaster.
【0015】(比較例1)実施例1の処方からイリス根
エキスを除いた他は実施例1と同様にして貼付剤を製造
した。 (比較例2)実施例1の処方からインドメタシンを除い
た他は実施例1と同様にして貼付剤を製造した。 (比較例3)実施例2の処方からイリス根エキスを除い
た他は実施例2と同様にして硬膏剤を製造した。これら
実施例及び比較例で製造した製剤の処方を表1及び表2
に示す。Comparative Example 1 A patch was prepared in the same manner as in Example 1 except that the iris root extract was omitted from the formulation of Example 1. (Comparative Example 2) A patch was produced in the same manner as in Example 1 except that indomethacin was omitted from the formulation of Example 1. Comparative Example 3 A plaster was produced in the same manner as in Example 2 except that the iris root extract was omitted from the formulation of Example 2. Tables 1 and 2 show the formulations of the preparations produced in these Examples and Comparative Examples.
Shown in
【0016】[0016]
【表1】 [Table 1]
【0017】[0017]
【表2】 [Table 2]
【0018】(試験例)実施例及び比較例で製造した製
剤の圧刺激試験を実施し、製剤の鎮痛作用を検討した。
試験方法はWister系雄性ラット(120〜150g)を1
群6匹として用いた。ラット左後足蹠皮下に20%イー
スト懸濁液0.1mlを投与した。起炎剤注射前及び注
射3時間後にanalgesy meter(Ugo basile社製)を用いて
もがき様反応を指標として頭痛閾値を測定した。この時
の痛みの閾値が各群間でほぼ同じになるようにグルーピ
ングを行った。グルーピング後すぐに、2.5cm×3.5
cmに予め切断した被験物質を投与し、伸縮性包帯で固定
した。被験物質投与3、5時間後に痛みの閾値を測定し
た。起炎剤注射後の疼痛閾値から下記に示す計算方法に
て、疼痛閾値の上昇率を求めた。(Test Example) A pressure stimulation test was performed on the preparations produced in Examples and Comparative Examples, and the analgesic action of the preparations was examined.
The test method was as follows: 1 male Wister rat (120-150 g)
It was used as a group of 6 animals. 0.1 ml of a 20% yeast suspension was subcutaneously administered to the rat's left hind footpad. The headache threshold was measured using an analgesy meter (manufactured by Ugo basile) before and 3 hours after the injection of the proinflammatory agent, using the postcard-like reaction as an index. Grouping was performed so that the pain threshold at this time was substantially the same between the groups. Immediately after grouping, 2.5cm x 3.5
The test substance previously cut into cm was administered, and fixed with an elastic bandage. The pain threshold was measured 3, 5 hours after the administration of the test substance. From the pain threshold value after injection of the proinflammatory drug, the rate of increase of the pain threshold value was determined by the following calculation method.
【0019】[0019]
【数1】 (Equation 1)
【0020】結果を表3及び表4に示す。The results are shown in Tables 3 and 4.
【0021】[0021]
【表3】 [Table 3]
【0022】[0022]
【表4】 [Table 4]
Claims (1)
根抽出液及びそのエキスからなる群より選ばれる1種ま
たは2種を配合した消炎鎮痛貼付剤。1. An anti-inflammatory analgesic patch comprising (a) indomethacin and (b) one or two selected from the group consisting of an iris root extract and an extract thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8319144A JPH10158186A (en) | 1996-11-29 | 1996-11-29 | Antiinflammatory analgesic patch |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8319144A JPH10158186A (en) | 1996-11-29 | 1996-11-29 | Antiinflammatory analgesic patch |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10158186A true JPH10158186A (en) | 1998-06-16 |
Family
ID=18106941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8319144A Pending JPH10158186A (en) | 1996-11-29 | 1996-11-29 | Antiinflammatory analgesic patch |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10158186A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018210A1 (en) * | 2005-08-10 | 2007-02-15 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch less irritative to skin |
-
1996
- 1996-11-29 JP JP8319144A patent/JPH10158186A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018210A1 (en) * | 2005-08-10 | 2007-02-15 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch less irritative to skin |
JP2007045738A (en) * | 2005-08-10 | 2007-02-22 | Hisamitsu Pharmaceut Co Inc | Plaster with reduced skin irritation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5052558B2 (en) | Gel ointment | |
JP4596751B2 (en) | Anti-inflammatory analgesic patch | |
JP4677063B2 (en) | Dutch mustard extract combination external preparation | |
JPH0739748A (en) | Low temperature crosslinked type gel agent | |
CN111825548B (en) | Pharmaceutical composition containing aryl propionic acid compound | |
JP3091285B2 (en) | External anti-inflammatory analgesic | |
JP2001199883A (en) | External preparation for antiinflammatory analgesic purpose | |
JPH0662401B2 (en) | Ketoprofen-containing patch | |
KR20190049529A (en) | Composition | |
JPH057370B2 (en) | ||
JPH10158186A (en) | Antiinflammatory analgesic patch | |
JP3145857B2 (en) | Aqueous warming patch | |
JP3612731B2 (en) | Anti-inflammatory analgesic topical | |
JP2000143513A (en) | Composition for external use | |
CA2203566C (en) | Percutaneously administration preparation | |
JPH11180887A (en) | Anti-inflammatory analgesic patch | |
JPH0555485B2 (en) | ||
WO2020035789A1 (en) | Migraine relieving topical patch and its process of preparation | |
JP4038580B2 (en) | Patch | |
JP2764261B2 (en) | External anti-inflammatory analgesic | |
JPH0525855B2 (en) | ||
KR20020068386A (en) | Remedies for external use for allergic skin diseases | |
JP2000297036A (en) | Anti-inflammatory and analgesic agent for external use | |
JPH0276816A (en) | External preparation | |
JP2008231081A (en) | Ketoprofen-containing external preparation |